2 Retailers Collapsing Post-Earnings; A Devastating Development for One Drug Stock

Cytokinetics stock is crumbling after its ALS drug failed a late-stage trial

Managing Editor
Nov 21, 2017 at 10:21 AM
facebook X logo linkedin


U.S. stocks are surging this morning following a fresh round of earnings reports, with the S&P 500 Index (SPX) and Nasdaq Composite (IXIC) fresh off record highs. However, jewelry maker Signet Jewelers Ltd. (NYSE:SIG), shoe peddler DSW Inc. (NYSE:DSW), and biotech Cytokinetics, Inc. (NASDAQ:CYTK) are three stocks currently short-sale restricted (SSR), after barreling lower this morning. Here's a closer look at what's moving shares of SIG, DSW, and CYTK.

SIG Stock Slides On Surprise Loss, Slashed Outlook

Signet Jewelers stock is down 26.3% to trade at $55.91, after the company reported an unexpected third-quarter loss and revenue miss on disappointing same-store sales. The jeweler also cut its fiscal 2018 outlook. SIG stock has shed over 40% year-to-date, and is now trading at its lowest point since an earnings-induced second-quarter bull gap in late August.

Short sellers are likely cheering the collapse. Even though the stock is SSR today, short interest increased by 14.6% during the last reporting period to 15.47 million shares, a hefty 28% of SIG's total available float.

Dismal Earnings Bury DSW Stock

DSW stock is down 10.8% to trade at $20.10, after the firm reported third-quarter earnings that fell short of analyst expectations. The shoe retailer, which cited a negative impact from hurricanes as a reason for the subpar results, also cut its fiscal 2017 guidance. DSW stock had tacked on 44% over the past three months, and may have been due for a short-term pullback. Specifically, its 14-day Relative Strength Index (RSI) closed last night at 71, in "overbought" territory.

This earnings reaction is just what short sellers were looking for. Short interest increased by almost 14% during the last two reporting periods to 12.48 million shares, a six-year high. This represents 19% of DSW's total available float.

Cytokinetics Stock Plummets After Pulling ALS Drug

Shares of Cytokinetics are down a whopping 30% to trade at $7.78, earlier hitting a new 20-month low of $7.00, after the biotech abandoned its treatment for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, due to failed late-stage trials. CYTK stock has now shed 37.2% in 2017 -- and downgrades are certainly a high probability, considering all seven of the brokerages covering CYTK stock rate it a "buy" or "strong buy."

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI